skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Index

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Byrd, John C ; Harrington, Bonnie ; O'Brien, Susan ; Jones, Jeffrey A ; Schuh, Anna ; Devereux, Steve ; Chaves, Jorge ; Wierda, William G ; Awan, Farrukh T ; Brown, Jennifer R ; Hillmen, Peter ; Stephens, Deborah M ; Ghia, Paolo ; Barrientos, Jacqueline C ; Pagel, John M ; Woyach, Jennifer ; Johnson, Dave ; Huang, Jane ; Wang

The New England journal of medicine, 28 January 2016, Vol.374(4), pp.323-32 [Peer Reviewed Journal]

Full text available

View all versions
Citations Cited by
  • Title:
    Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
  • Author: Byrd, John C ; Harrington, Bonnie ; O'Brien, Susan ; Jones, Jeffrey A ; Schuh, Anna ; Devereux, Steve ; Chaves, Jorge ; Wierda, William G ; Awan, Farrukh T ; Brown, Jennifer R ; Hillmen, Peter ; Stephens, Deborah M ; Ghia, Paolo ; Barrientos, Jacqueline C ; Pagel, John M ; Woyach, Jennifer ; Johnson, Dave ; Huang, Jane ; Wang
  • Description: Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors. In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion. The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated immunoglobulin heavy-chain variable genes. No dose-limiting toxic effects occurred during the dose-escalation portion of the study. The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), and increased weight (in 26%). Most adverse events were of grade 1 or 2. At a median follow-up of 14.3 months, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease. Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%. No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred. In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).
  • Is Part Of: The New England journal of medicine, 28 January 2016, Vol.374(4), pp.323-32
  • Identifier: E-ISSN: 1533-4406 ; PMID: 26641137 Version:1 ; DOI: 10.1056/NEJMoa1509981
  • Subjects: Antineoplastic Agents -- Administration & Dosage ; Benzamides -- Administration & Dosage ; Leukemia, Lymphocytic, Chronic, B-Cell -- Drug Therapy ; Protein-Tyrosine Kinases -- Antagonists & Inhibitors ; Pyrazines -- Administration & Dosage
  • Language: English

Searching Remote Databases, Please Wait